We are committed to finding effective treatment for life-threatening infectious diseases.
A Game Changer in Antibacterials Treatment for Gram-negative bacteria, Ultimate Target of N-Rephasin® Technology
Eco-friendly, no Side-effects, Unique mode of action. Bacteriophages and Antibiotic Resistance in Bacteria
New Generation of Heme-Iron (Porphyrin-Fe) Novel concept iron deficiency anemia therapeutic agent
We have been running our website following the launch of fully re-designed Korean website on January 18 2017. Our primary goal with the reworked website was to strengthen communications with shareholders and investors, and provide news and updates regarding the development and progress of the......
Kyungwon Yoon(CEO) of iNtRON Biotechnology, Inc. said on March 7, 2017 that Tonabacase, as global new drug substance name for 'N-Rephasin® SAL200 which is a novel superbacterial infection treatment drug, is adopted and registered by International Nonproprietary Name(INN), an affiliated organization of WHO....
1950s was the golden age of antibiotics development. However, overuse and misuse of antibiotics caused the dramatic increase of bacterial resistance to antibiotics, and at the same time, the antibiotics development market decreased dramatically....
iNtRON Bio has been focusing on the R&D investment since its foundation and accelerate development speed after the IPD in KOSDAQ. We are aiming for the ‘global R&D company’ ; and promoting the value of the company focused on the BIO New Drug by developing various ‘First-in-Class’ bio-drugs and conducting clinical studies in phases.
